ViGenCell Inc. (KOSDAQ:308080)

Market Cap	57.36B
Revenue (ttm)	278.95M
Net Income (ttm)	-12.56B
Shares Out	20.45M
EPS (ttm)	-650.72
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,216
Average Volume	33,726
Open	2,810.00
Previous Close	2,805.00
Day's Range	2,775.00 - 2,835.00
52-Week Range	2,305.00 - 4,560.00
Beta	1.10
RSI	36.75
Earnings Date	Aug 14, 2025

About ViGenCell

ViGenCell Inc. specializes in immune cell therapy. It develops ViTier, a T-cell therapy platform that uses antigen-specific killer T cells to target and remove cancer cells; ViRanger, a T-cell gene therapy platform that uses innate killer T cells to target and eliminate abnormal cells; and ViMedier, an immunosuppressive cell therapy platform that uses the differentiation and expansion of cord blood derived myeloid suppressor cells for universal use. The company was founded in 1995 and is based in Seoul, South Korea.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1995
• Employees: 64
• Stock Exchange: KOSDAQ
• Ticker Symbol: 308080